[Ip-health] Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIH Funding in Key Gleevec Patent | Bill of Health

James Love james.love at keionline.org
Fri Oct 11 08:57:33 PDT 2019

After 18 years, Novartis gets around to disclosing NIH funding in a Gleevec



This is a story about U.S. patent number 6,958,335, and how it took more
than 18 years for Novartis to acknowledge National Institutes of Health
(NIH) funding in a key patent for Gleevec, allowing Novartis to shape the
narrative regarding its role in the development of Gleevec, and also to
avoid demands that Novartis make the invention “available to the public on
reasonable terms,” which is an obligation under the Bayh-Dole Act.

More information about the Ip-health mailing list